Clinical Trials Browser

Active not recruiting × Lymphoma, B-Cell, Marginal Zone × 30 days × Clear all

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03625037 2026-04-08

EPCORE™ NHL-1

Phase 1/2 Active not recruiting

666 enrolled 4 FDA

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03697512 2026-04-08

MALIBU

Phase 2 Active not recruiting

175 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

78 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

Phase 2 Active not recruiting

26 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07480863 2026-04-02

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Phase 2 Active not recruiting

65 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05753501 2026-03-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Phase 1 Active not recruiting

135 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Phase 1 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

EPCORE™ NHL-1

MALIBU

EPCORE™ NHL-3

Study of Acalabrutinib and Tafasitamab in MZL Patients

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma